Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of PDZ domain binding Kinase inhibition using TOPK-32 (called PBKi) on C4-2 cell transcriptome

ABSTRACT: Analysis of C4-2 prostate cancer cell line after 6 hrs of treatment with TOPK-32. PBK is overexpressed in a number of solid tumours, including prostate cancer. Results provide insight into the molecular mechanisms of PBK in prostate carcinogenesis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE64341 | GEO | 2018/08/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of PBK knockdown on C4-2 cell transcriptome

Project description:Analysis of C4-2 Prostate cancer cell line after 72 hours of knockdown. PBK is overexpressed in a number of solid tumours, including prostate cancer. Results provide insight into the molecular mechanisms of PBK in prostate carcinogenesis.

2018-08-30 | GSE63701 | GEO

Effect of CHKA knockdown on C4-2 cell transcriptome

Project description:Analysis of C4-2 Prostate cancer cell line after 72 hours of knockdown. CHKA is overexpressed in a number of solid tumours, including prostate cancer. Results provide insight into the molecular mechanisms of CHKA in prostate carcinogenesis.

2015-11-18 | GSE63700 | GEO

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

Project description:Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for enzalutamide resistance in C4-2B-MDVR cells. Enzalutamide resistant C4-2B-MDVR cells were selected from C4-2B cells during long time enzalutamide treatment. Genes responsible for enzalutamide resistance were identified using C4-2B vs. C4-2B-MDVR RNA extraction and hybridization on Affymetrix microarrays.

2015-04-09 | E-GEOD-64143 | biostudies-arrayexpress

FASN inhibition in prostate cancer cells C4-2

Project description:Fatty acid synthase (FASN) inhibition effect with IPI-9119 compound in prostate cancer cells C4-2

2024-02-01 | GSE224323 | GEO

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells

2015-04-09 | GSE64143 | GEO

Paxillin regulates genomic networks in prostate cancer [C4-2]

Project description:We report that the adaptor protein, paxillin, regulates some androgen responsive genes in the castration resistant prostate cancer cell line,C4-2.

2019-08-01 | GSE131728 | GEO

Genome-wide analysis of gene expression in isoflavone and 3,3’-diindolylmethane treated C4-2B prostate cancer cells

Project description:Expression profiling of isoflavone and 3,3’-diindolylmethane treated C4-2B prostate cancer cells was conducted using Affymetrix Human Genome U133 Plus 2.0. Array C4-2B prostate cancer cells were treated with isoflavone and B-DIM for 6 hours or longer up to 72 hours. Gene expression profiling was conducted

2012-01-25 | E-GEOD-35324 | biostudies-arrayexpress

RNA sequencing of RRM2 knockdown in C4-2 cells

Project description:Human prostate cancer C4-2 cells transfected with siRNAs (siNS and siRRM2). Knockdown were confirm by westernblot or qPCR. Transfected cells were prepared for RNA-seq.

2020-02-20 | GSE117924 | GEO

RNA sequencing of COH29 treatment in C4-2 cells

Project description:Human prostate cancer C4-2 cells treated with COH29 and DMSO. Cells were treated with DMSO, 10uM or 20 uM COH29 for 48 hours. Cells were prepared for RNA-seq.

2020-02-20 | GSE117921 | GEO

Genome wide expression change by Tet-O-YAP5SA C4-2 cells treated with/without Dox

Project description:to investigate the role of activated YAP in prostate cancer progression. C4-2 cells were used as the model.

2022-11-13 | GSE217580 | GEO